Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
Cybin Inc., a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference, scheduled for September 3–5, 2025. The session will be webcast live on Friday, September 5, at 10:20 a.m. ET, with an archived replay available on Cybin’s investor relations website. This engagement provides a platform to discuss the company's progress in developing next-generation treatments for mental healthcare, an area with substantial unmet needs.
The company is advancing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer significant improvements over existing therapies. Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder. These investigational compounds are part of a broader research pipeline focused on 5-HT-receptor targeted therapies, aiming to provide effective and durable results for patients.
Cybin's participation in high-profile conferences like the Cantor Global Healthcare Conference is crucial for raising awareness among investors and stakeholders about the evolving landscape of mental health treatments. The company's work addresses critical gaps in mental healthcare, where current options often fall short in efficacy and durability. For more details, the full press release can be accessed at https://ibn.fm/N8ObB.
The latest news and updates relating to Cybin are available in the company’s newsroom at https://ibn.fm/CYBN. This ongoing communication helps maintain transparency and engagement with the investment community, which is vital for a clinical-stage company navigating complex regulatory pathways and seeking to bring innovative treatments to market.